Key Points
- DaVita CFO Joel Ackerman sold 51,471 shares on May 7 for about $9.89 million, reducing his ownership by 27.99%.
- The company beat quarterly expectations, reporting EPS of $2.87 versus $2.33 expected and revenue of $3.42 billion, up 6% year over year.
- Analysts turned more bullish on DVA, with recent target hikes from firms like Deutsche Bank and UBS pushing the average price target to about $199.17.
DaVita Inc. (NYSE:DVA - Get Free Report) CFO Joel Ackerman sold 51,471 shares of the business's stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total value of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company's stock, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
DaVita Trading Up 0.1%
Shares of NYSE:DVA opened at $198.87 on Tuesday. The stock has a 50 day moving average of $154.92 and a 200 day moving average of $133.69. The company has a market cap of $12.77 billion, a PE ratio of 18.45, a price-to-earnings-growth ratio of 0.65 and a beta of 0.84. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $202.13.
DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm's revenue was up 6.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts predict that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on DVA. Deutsche Bank Aktiengesellschaft upgraded DaVita from a "hold" rating to a "buy" rating and upped their price target for the stock from $126.00 to $220.00 in a research note on Wednesday, May 6th. UBS Group upped their price target on DaVita from $190.00 to $235.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. TD Cowen upped their price target on DaVita from $144.00 to $201.00 and gave the stock a "hold" rating in a research note on Monday. Finally, Barclays upped their price target on DaVita from $158.00 to $194.00 and gave the stock an "equal weight" rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $199.17.
Read Our Latest Stock Analysis on DVA
Institutional Trading of DaVita
Several hedge funds have recently modified their holdings of DVA. Root Financial Partners LLC raised its holdings in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company's stock worth $29,000 after acquiring an additional 105 shares in the last quarter. Elevation Wealth Partners LLC raised its holdings in shares of DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company's stock worth $31,000 after acquiring an additional 165 shares in the last quarter. Caitlin John LLC purchased a new stake in shares of DaVita during the 4th quarter worth approximately $34,000. Sankala Group LLC purchased a new stake in shares of DaVita during the 4th quarter worth approximately $39,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of DaVita during the 2nd quarter worth approximately $43,000. 90.12% of the stock is owned by hedge funds and other institutional investors.
About DaVita
(
Get Free Report)
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
